Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use

Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-04, Vol.15 (4), p.e37441
Main Authors: Pacheco, Curtis S, White, Kevin M
Format: Article
Language:English
Subjects:
Allergy/Immunology
Asymptomatic
Biopsy
Case reports
Dermatitis
Dermatology
Etiology
Immunology
Inflammation
Monoclonal antibodies
Otolaryngology
Patients
Sinuses
Steroids
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c267t-fadc4bc6a0e7f73668a12b2a67a6e4c815e92d71c16ddf6165ce6c1ffadc71cb3
container_end_page
container_issue 4
container_start_page e37441
container_title Curēus (Palo Alto, CA)
container_volume 15
creator Pacheco, Curtis S
White, Kevin M
description Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and ocular surface reactions; however, a variety of both acute and delayed cutaneous reactions have also been described. We present a case of delayed hyperpigmented injection site reactions following chronic dupilumab use.
doi_str_mv 10.7759/cureus.37441
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10174336</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2821266520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c267t-fadc4bc6a0e7f73668a12b2a67a6e4c815e92d71c16ddf6165ce6c1ffadc71cb3</originalsourceid><addsrcrecordid>eNpVUF1LwzAUDaK4MffmsxR8tTNJ26R7EtnUDQaCuueQprdbRtvUpBX2780-HPPp3nPvueceDkK3BI84T8aPqrPQuVHE45hcoD4lLA1TksaXZ30PDZ3bYIwJ5hRzfI16EScpxSzqo8UUSrmFPJhtG7CNXlVQtx7O6w2oVps6-NQtBB8g98gF0w6C1gSTtTW1Vh42uuwqmQVLBzfoqpClg-GxDtDy9eVrMgsX72_zyfMiVJTxNixkruJMMYmBFzxiLJWEZlQyLhnEKiUJjGnOiSIszwtGWKKAKVLs7vw0iwbo6aDbdFkFufKWrSxFY3Ul7VYYqcX_Ta3XYmV-BMGEx1HEvML9UcGa7w5cKzams7U3LWhKCWUsodizHg4sZY1zForTC4LFLn9xyF_s8_f0u3NbJ_Jf2tEv40aDrw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2821266520</pqid></control><display><type>article</type><title>Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Pacheco, Curtis S ; White, Kevin M</creator><creatorcontrib>Pacheco, Curtis S ; White, Kevin M</creatorcontrib><description>Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and ocular surface reactions; however, a variety of both acute and delayed cutaneous reactions have also been described. We present a case of delayed hyperpigmented injection site reactions following chronic dupilumab use.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.37441</identifier><identifier>PMID: 37182063</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Allergy/Immunology ; Asymptomatic ; Biopsy ; Case reports ; Dermatitis ; Dermatology ; Etiology ; Immunology ; Inflammation ; Monoclonal antibodies ; Otolaryngology ; Patients ; Sinuses ; Steroids</subject><ispartof>Curēus (Palo Alto, CA), 2023-04, Vol.15 (4), p.e37441</ispartof><rights>Copyright © 2023, Pacheco et al.</rights><rights>Copyright © 2023, Pacheco et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Pacheco et al. 2023 Pacheco et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c267t-fadc4bc6a0e7f73668a12b2a67a6e4c815e92d71c16ddf6165ce6c1ffadc71cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2821266520/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2821266520?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37182063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pacheco, Curtis S</creatorcontrib><creatorcontrib>White, Kevin M</creatorcontrib><title>Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and ocular surface reactions; however, a variety of both acute and delayed cutaneous reactions have also been described. We present a case of delayed hyperpigmented injection site reactions following chronic dupilumab use.</description><subject>Allergy/Immunology</subject><subject>Asymptomatic</subject><subject>Biopsy</subject><subject>Case reports</subject><subject>Dermatitis</subject><subject>Dermatology</subject><subject>Etiology</subject><subject>Immunology</subject><subject>Inflammation</subject><subject>Monoclonal antibodies</subject><subject>Otolaryngology</subject><subject>Patients</subject><subject>Sinuses</subject><subject>Steroids</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpVUF1LwzAUDaK4MffmsxR8tTNJ26R7EtnUDQaCuueQprdbRtvUpBX2780-HPPp3nPvueceDkK3BI84T8aPqrPQuVHE45hcoD4lLA1TksaXZ30PDZ3bYIwJ5hRzfI16EScpxSzqo8UUSrmFPJhtG7CNXlVQtx7O6w2oVps6-NQtBB8g98gF0w6C1gSTtTW1Vh42uuwqmQVLBzfoqpClg-GxDtDy9eVrMgsX72_zyfMiVJTxNixkruJMMYmBFzxiLJWEZlQyLhnEKiUJjGnOiSIszwtGWKKAKVLs7vw0iwbo6aDbdFkFufKWrSxFY3Ul7VYYqcX_Ta3XYmV-BMGEx1HEvML9UcGa7w5cKzams7U3LWhKCWUsodizHg4sZY1zForTC4LFLn9xyF_s8_f0u3NbJ_Jf2tEv40aDrw</recordid><startdate>20230411</startdate><enddate>20230411</enddate><creator>Pacheco, Curtis S</creator><creator>White, Kevin M</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20230411</creationdate><title>Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use</title><author>Pacheco, Curtis S ; White, Kevin M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c267t-fadc4bc6a0e7f73668a12b2a67a6e4c815e92d71c16ddf6165ce6c1ffadc71cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allergy/Immunology</topic><topic>Asymptomatic</topic><topic>Biopsy</topic><topic>Case reports</topic><topic>Dermatitis</topic><topic>Dermatology</topic><topic>Etiology</topic><topic>Immunology</topic><topic>Inflammation</topic><topic>Monoclonal antibodies</topic><topic>Otolaryngology</topic><topic>Patients</topic><topic>Sinuses</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pacheco, Curtis S</creatorcontrib><creatorcontrib>White, Kevin M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pacheco, Curtis S</au><au>White, Kevin M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-04-11</date><risdate>2023</risdate><volume>15</volume><issue>4</issue><spage>e37441</spage><pages>e37441-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and ocular surface reactions; however, a variety of both acute and delayed cutaneous reactions have also been described. We present a case of delayed hyperpigmented injection site reactions following chronic dupilumab use.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>37182063</pmid><doi>10.7759/cureus.37441</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2023-04, Vol.15 (4), p.e37441
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10174336
source Publicly Available Content (ProQuest); PubMed Central
subjects Allergy/Immunology
Asymptomatic
Biopsy
Case reports
Dermatitis
Dermatology
Etiology
Immunology
Inflammation
Monoclonal antibodies
Otolaryngology
Patients
Sinuses
Steroids
title Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T15%3A21%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Delayed%20Hyperpigmented%20Injection%20Site%20Reactions%20Due%20to%20Chronic%20Dupilumab%20Use&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Pacheco,%20Curtis%20S&rft.date=2023-04-11&rft.volume=15&rft.issue=4&rft.spage=e37441&rft.pages=e37441-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.37441&rft_dat=%3Cproquest_pubme%3E2821266520%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c267t-fadc4bc6a0e7f73668a12b2a67a6e4c815e92d71c16ddf6165ce6c1ffadc71cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2821266520&rft_id=info:pmid/37182063&rfr_iscdi=true